Five Prime Therapeutics, Inc.

Elizabeth Bosch

Ernestine A Lee

Diane Hollenbaugh

Minmin Qin

Ali Sadra

Lewis T Williams

Stephen Kohl Doberstein

Kevin Hestir

Ge Wu

Justin Wong

Hongbing Zhang

Shannon Marshall

Haishan Lin

Cindy Leo

Aileen Zhou

Justin G P Wong

Dirk Behrens

Thomas Linnemann

Min Mei Huang

Robert Forgan Halenbeck

Justin G Wong

Steven Doberstein

Thomas Five Prime Therapeutics Inc Linnemann

The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Methods of treating disease with FGFR1 fusion proteins

FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC

Polynucleotides encoding FGFR1-IIIc ECD fusion proteins

Disclosed is a newly identified secreted molecule, identified herein as 'monocyte, granulocyte, and dendritic cell colony stimulating factor' (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.

Compositions and methods of use for MGD-CSF in disease treatment

FGFR2-IIIb fusion proteins and methods of making them

ECD carboxy-terminal deletion FGFR4 fusion proteins and methods of producing them

FGFR3-IIIc fusion proteins

Compositions and methods of treating disease with FGFR fusion proteins

Growing community of inventors

Cupertino, CA, United States of America

Elizabeth Bosch